04:45 PM EDT, 07/07/2025 (MT Newswires) -- Nanobiotix ( NBTX ) reported Monday two developments with the objective of boosting the positioning of product candidate JNJ-1900, which is licensed by Johnson & Johnson's ( JNJ ) Janssen Pharmaceutica.

Nanobiotix ( NBTX ) said authorities in European countries have agreed to reclassify JNJ-1900 from a medical device to a drug, which completes a process launched by Johnson & Johnson ( JNJ ) to harmonize the product candidate's regulatory status with classifications in place in the US and other markets.

Additionally, Nanobiotix ( NBTX ) said it has filed a new composition of matter patent for JNJ-1900 to reinforce the product candidate's intellectual property foundation.

JNJ-1900 is the subject of a global clinical development program in several tumor types and therapeutic combinations, including a phase 3 trial in head and neck cancer, Nanobiotix ( NBTX ) said.